Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 292
- Registration Number
- NCT02039505
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 157
- Registration Number
- NCT02038920
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT01981616
- Locations
- 🇬🇧
ICON Development Solutions, Manchester, United Kingdom
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 416
- Registration Number
- NCT01224171
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸Gastroenterology of the Rockies, Lafayette, Colorado, United States
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01177228
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2243
- Registration Number
- NCT00790933
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 895
- Registration Number
- NCT00783718
- Locations
- 🇺🇸
Gastroenterology Associates of Central Georgia, Macon, Georgia, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1116
- Registration Number
- NCT00783692
- Locations
- 🇺🇸
Puget Sound Medical Research, Edmonds, Washington, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Medical Center - Cancer Centers, Pittsburgh, Pennsylvania, United States
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00619489
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.